In This Article:
Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for challenging cancers.
The partnership integrates Leveragen's Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight Bio, aiming to improve the efficacy, persistence and functionality of the therapies, particularly for solid tumours.
Leveragen will take charge of discovering fully human single-domain antibodies against therapeutic targets and the preclinical development of the T-cell therapies will be managed by Moonlight Bio.
Moonlight Bio chief scientific officer Jordan Jarjour stated: “At Moonlight Bio, we are dedicated to delivering T-cell therapies that break through barriers obstructing successful outcomes in solid tumours – the vast majority of the global cancer disease burden.
“Leveragen’s Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T-cell therapies, particularly when combined with the tools and technologies that the Moonlight Bio team is advancing.”
The Singularity Sapiens Mouse platform is engineered to produce chain-only antibodies derived from the entire human VH repertoire, incorporated directly into the mouse genome.
It optimises the development of B cells and produces immune responses.
This speeds up the discovery of therapeutic modalities such as messenger ribonucleic acid-based treatments, antibody-drug conjugates, the chimeric antigen receptor-T and bispecifics.
Leveragen founder and CEO Weisheng Chen stated: “Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.”
Based in Seattle, Washington, Moonlight Bio aims to develop potency-enhanced T-cell therapies, offering new hope to cancer patients.
In July 2024, Leveragen made a research, option and licence agreement with Moderna to advance the development of various therapeutics.
"Leveragen and Moonlight Bio unite for T-cell therapy development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.